Although many kinds of therapies are applied in the clinic, drug-resistance is a major and
unavoidable problem. Another disturbing statistic is the limited number of drug targets, which …

Over the past two decades there has been a great deal of interest in the development of
inhibitors of the cyclin-dependent kinases (CDKs). This attention initially stemmed from …

Mediator is an essential, large, multisubunit, transcriptional co-activator highly conserved
across eukaryotes. Mediator interacts with gene-specific transcription factors at enhancers …

With the rapid development of biomedicine, people have a deeper understanding with the
biological characteristics of malignant tumors, and begin to notice that in most tumors, there …

Hormone therapy targeting estrogen receptor (ER) is the principal treatment for ER-positive
breast cancers. However, many cancers develop resistance to hormone therapy while …

The fact that many cancer types display transcriptional addiction driven by dysregulation of
oncogenic enhancers and transcription factors has led to increased interest in a group of …

The Mediator complex-associated cyclin-dependent kinase CDK8 has been implicated in
human disease, particularly in colorectal cancer where it has been reported as a putative …

Recent studies on cyclin-dependent kinase (CDK) inhibitors have revealed that small
molecule drugs have become very attractive for the treatment of cancer and …

The mediator complex-associated cyclin dependent kinase CDK8 regulates β-catenin-
dependent transcription following activation of WNT signaling. Multiple lines of evidence …

Cortistatin A is a natural product isolated from the marine sponge Corticium simplex and was
found to be a potent and selective inhibitor of CDK8. Many synthetic groups have reported …